QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that Babette Aicher,
PhD, Director of Preclinical Development, will be making a poster
presentation on updated proof-of-concept results for Disorazol Z
cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian
and endometrial cancer xenograft models, at the upcoming American
Association for Cancer Research ("AACR") annual meeting, which will be
held April 6-10, 2013, in Washington D.C. The study is funded through a
grant from the German Ministry of Education and Research.
|Abstract #5476:||"LHRH receptor targeting as mechanism of anti-tumor activity for
cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic
peptide D-Lys6-LHRH", B. Aicher, T. Schuster, L. Blumenstein, A. Schubert, C. Gruendker,
J.B. Engel, O. Ortmann, R. Mueller, E. Guenther, M. Gerlach, M. Teifel.
Experimental and Molecular Therapeutics 37
|Date & Time:||
Wednesday, April 10, 2013, from 8:00 a.m. to 12:00 p.m. (eastern)
Hall A-C Poster Section 36, Walter E. Washington Convention Center
About Disorazol Z
Disorazol Z is a novel natural compound, with outstanding cytotoxic
activity, isolated from the myxobacterium Sorangium cellulosum. Disorazol Z, a macrocyclic polyketide, is produced by a fermentation
process providing high yield and purity. Besides tubulin binding,
Disorazol Z has pro-apoptotic properties and has been shown to arrest
cancer cells in G2 stage of the cell cycle at subnanomolar
concentrations. Disorazol Z is an ideal partner for the formation of
cytotoxic conjugates with peptides, proteins, and antibodies to
selectively target cancer cells.
About Disorazol Z cytotoxic conjugates such as AEZS-125 and AEZS-138
AEZS-125 and AEZS-138 are novel cytotoxic conjugates based on the
natural compound Disorazol Z and the luteinizing hormone-releasing
hormone ("LHRH") receptor agonist D-Lys6-LHRH. The peptide part directs the conjugates specifically to LHRH
receptor expressing tumor cells, and mediates binding and uptake via
endocytosis. Within the cancer cell, the conjugates are cleaved and
Disorazol Z can deploy its potent anti-proliferative activity.
According to the literature, LHRH receptors occur in a number of human
tumors, specifically in about 80% of ovarian and endometrial cancers.
They are also expressed in prostate, urinary bladder and
triple-negative breast cancer, while they are rarely found in normal
tissues, except for the pituitary gland and reproductive organs. The
LHRH receptor displays ideal properties for selective drug targeting.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information, visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.